In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.
In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.
Atea Pharmaceuticals, Inc. Customers
No clients on recordNo downstream customers found in our database for Atea Pharmaceuticals, Inc..
Atea Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AVIR-DEBT-7994
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
AVIR-DEBT
Debt stack $634,000
90%
Market cache reports total debt of $634,000.
Atea Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Atea Pharmaceuticals, Inc..
Atea Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
AVIR-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 129 tracked holders.
Atea Pharmaceuticals, Inc. Extended Supply Chain Network